Photo of Jill A. Macoska,  PhD

Jill A. Macoska, PhD

University Of Massachusetts - Boston

University Of Massachusetts - Boston
Phone: (617) 287-5783


Jill.Macoska@umb.edu

Jill A. Macoska, PhD

University Of Massachusetts - Boston

EDUCATIONAL TITLES

  • Alton J. Brann Distinguished Professor in Science and Mathematics, Biology, University Of Massachusetts - Boston
  • Director, Center for Personalized Cancer Therapy, University Of Massachusetts - Boston
  • Presidential Scholar, President's Office, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am currently the Alton J. Brann Endowed Chair and Professor of Biological Sciences at the University of Massachusetts Boston. I have led peer-reviewed and funded research for the past 20 years focused on elucidating the molecular genetic alterations and dysfunctional intracellular signaling mechanisms that promote prostate pathobiology. Research in the Macoska laboratory is currently focused on: 1) Defining the mechanisms through which dysfunctional paracrine interactions between diverse cell types – epithelial, fibroblastic, endothelial, leukocytic – develop consequent to the aging process, and how these dysfunctional interactions contribute to the development of benign and malignant proliferative disease in the prostate; 2) Elucidating the intracellular mechanisms through which growth factors, particularly CXC-type chemokines, secreted by aging stromal fibroblasts stimulate cellular proliferation and myofibroblast phenoconversion in the lower urinary tract, and the association of these pathobiologies with urinary voiding dysfunction and malignancy, and 3) Translating laboratory-based knowledge to the development of clinically efficacious therapeutics to slow or arrest the initiation or progression of benign and malignant disease in the prostate. I am the past Secretary and current President-elect of the Society for Basic Urologic Research. I have trained >20 pre- and post-doctoral scientists in laboratory research and am vested in facilitating and ensuring the successful training of the next generation of biomedical researchers.

Publications

Powered by Harvard Catalyst
  • Gharaee-Kermani M, Mehra R, Robinson DR, Wei JT, Macoska JA. Complex cellular composition of solitary fibrous tumor of the prostate. Am J Pathol 2014; 184:732-9. PubMed
  • Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Current Urology Reports 2013; 14:628-37. PubMed
  • Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 2013. PubMed
  • Gharaee-Kermani M, Rodriguez-Nieves JA, Mehra R, Vezina CA, Sarma AV, Macoska JA. Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model. Prostate 2013; 73:1123-33. PubMed
  • Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate 2013; 73:573-81. PubMed
  • Chen W, Weng S, Zhang F, Allen S, Li X, Bao L, Lam RH, Macoska JA, Merajver SD, Fu J. Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano 2013; 7:566-75. PubMed
  • Macoska J. Prostatic Fibrosis Is Associated With Lower Urinary Tract Symptoms. J Urol 2012. PubMed
  • Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol 2012; 188:1375-81. PubMed
  • Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol 2012; 351:249-63. PubMed
  • Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE 2012; 7:e49278. PubMed
  • Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa Tumor Microenvironment. Cancer Microenviron 2011; 4:283-97. PubMed
  • McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA. Leukocytic promotion of prostate cellular proliferation. Prostate 2010; 70:377-89. PubMed
  • Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010; 3:90-9. PubMed
  • Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta KJ. Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem 2008; 104:2298-309. PubMed
  • Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res 2008; 36:2446-56. PubMed
  • Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 2008; 68:442-52. PubMed
  • Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008; 31:476-82. PubMed
  • Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate cancer progression. Neoplasia 2008; 10:244-54. PubMed
  • Begley LA, MacDonald JW, Day ML, Macoska JA. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 2007; 282:26767-74. PubMed
  • Macoska JA. Ancestry, genetic susceptibility, E-cadherin-160A and prostate cancer risk-is there an association? J Urol 2006; 176:435-6. PubMed
  • Barrett JM, Rovedo MA, Tajuddin AM, Jilling T, Macoska JA, MacDonald J, Mangold KA, Kaul KL. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII. Prostate 2006; 66:632-50. PubMed
  • Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 2005; 4:291-8. PubMed
  • Ricke WA, Macoska JA, Cunha GR. Developmental, cellular and molecular biology of benign prostatic hyperplasia. Differentiation 2011; 82:165-7. PubMed
  • Macoska JA. Chemokines and BPH/LUTS. Differentiation 2011; 82:253-60. PubMed
  • Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, Lee CT. -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 2008; 58:323-31. PubMed
Hide